Leqvio FDA Approval History
Last updated by Judith Stewart, BPharm on July 18, 2023.
FDA Approved: Yes (First approved December 22, 2021)
Brand name: Leqvio
Generic name: inclisiran
Dosage form: Injection
Company: Novartis Pharmaceuticals Corporation
Treatment for: High Cholesterol, Familial Heterozygous
Leqvio (inclisiran) is a small interfering RNA (siRNA) directed to PCSK9 (proprotein convertase subtilisin kexin type 9) mRNA used to reduce low-density lipoprotein cholesterol (LDL-C).
- Leqvio is indicated as an adjunct to diet and statin therapy for the treatment of adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), to reduce low-density lipoprotein cholesterol (LDL-C).
- Leqvio is administered via subcutaneous injection every six months, after the initial dose and another dose at three months.
- Common adverse reactions include injection site reaction, arthralgia, urinary tract infection, diarrhea, bronchitis, pain in extremity, and dyspnea.
Development timeline for Leqvio
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.